Home/Pipeline/Gavocabtagene autoleucel

Gavocabtagene autoleucel

Autoimmune Diseases

Phase 1/2Active

Key Facts

Indication

Autoimmune Diseases

Phase

Phase 1/2

Status

Active

Company

Astellas

About Astellas

Astellas Pharma is a major global pharmaceutical company with a mission to deliver innovative, patient-centric healthcare solutions. Formed in 2005 from the merger of Yamanouchi and Fujisawa, it has established a robust pipeline and commercial portfolio across oncology, urology, immunology, and other therapeutic areas. The company's strategy is built on a multi-modal R&D engine focused on cutting-edge biology, complemented by aggressive external innovation and a strategic push into digital health through its Rx+ and HealthX initiatives to drive sustainable growth.

View full company profile

Therapeutic Areas

Oncology Urology Immunology Ophthalmology Women's Health

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active
I&I Portfolio	Third Arc Bio	Pre-clinical	Active
Undisclosed Platform Programs	Zag Bio	Preclinical	Active
E-602	Palleon Pharmaceuticals	IND-Enabling	Active
DIASPOT Platform Expansion	DIAsource ImmunoAssays	Commercial & Development	Active
Platform Application for Autoimmune Diseases	ALTUCELL	Pre-clinical/Research	Active